The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

ILD incidence in RA patients similar in tofacitinib- and placebo-exposed patients (PMID 32826657)

Publications

Verstockt B, Pouillon L, Bossuyt P

Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath.

Journal of Crohn's & colitis 2021 Apr 06;15;692-693 — 2021 Apr 06 — 692-693

Gosangi B, Davids M, Somarouthu B, Alessandrino F, Giardino A, Ramaiya N, Krajewski K

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

Cancer imaging : the official publication of the International Cancer Imaging Society 2018 Apr 18;18;13 — 2018 Apr 18 — 13